Lixte Biotechnology (LIXT) Competitors $1.98 +0.07 (+3.66%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrends LIXT vs. CARM, PIRS, APRE, MEIP, SYBX, PRPH, CYTH, BLRX, ATHE, and FLGCShould you be buying Lixte Biotechnology stock or one of its competitors? The main competitors of Lixte Biotechnology include Carisma Therapeutics (CARM), Pieris Pharmaceuticals (PIRS), Aprea Therapeutics (APRE), MEI Pharma (MEIP), Synlogic (SYBX), ProPhase Labs (PRPH), Cyclo Therapeutics (CYTH), BioLineRx (BLRX), Alterity Therapeutics (ATHE), and Flora Growth (FLGC). These companies are all part of the "pharmaceutical products" industry. Lixte Biotechnology vs. Carisma Therapeutics Pieris Pharmaceuticals Aprea Therapeutics MEI Pharma Synlogic ProPhase Labs Cyclo Therapeutics BioLineRx Alterity Therapeutics Flora Growth Carisma Therapeutics (NASDAQ:CARM) and Lixte Biotechnology (NASDAQ:LIXT) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, community ranking, profitability, earnings, analyst recommendations, valuation and risk. Which has higher earnings and valuation, CARM or LIXT? Lixte Biotechnology has lower revenue, but higher earnings than Carisma Therapeutics. Lixte Biotechnology is trading at a lower price-to-earnings ratio than Carisma Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCarisma Therapeutics$20.27M0.86-$86.88M-$1.56-0.27Lixte BiotechnologyN/AN/A-$5.09M-$1.73-1.14 Do insiders and institutionals have more ownership in CARM or LIXT? 44.3% of Carisma Therapeutics shares are held by institutional investors. Comparatively, 5.1% of Lixte Biotechnology shares are held by institutional investors. 12.6% of Carisma Therapeutics shares are held by company insiders. Comparatively, 14.8% of Lixte Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Does the MarketBeat Community favor CARM or LIXT? Carisma Therapeutics received 16 more outperform votes than Lixte Biotechnology when rated by MarketBeat users. CompanyUnderperformOutperformCarisma TherapeuticsOutperform Votes1676.19% Underperform Votes523.81% Lixte BiotechnologyN/AN/A Is CARM or LIXT more profitable? Lixte Biotechnology has a net margin of 0.00% compared to Carisma Therapeutics' net margin of -314.78%. Carisma Therapeutics' return on equity of -957.20% beat Lixte Biotechnology's return on equity.Company Net Margins Return on Equity Return on Assets Carisma Therapeutics-314.78% -957.20% -96.39% Lixte Biotechnology N/A -5,562.77%-130.48% Do analysts rate CARM or LIXT? Carisma Therapeutics presently has a consensus target price of $4.94, indicating a potential upside of 1,082.10%. Given Carisma Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Carisma Therapeutics is more favorable than Lixte Biotechnology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Carisma Therapeutics 0 Sell rating(s) 5 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.43Lixte Biotechnology 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more risk & volatility, CARM or LIXT? Carisma Therapeutics has a beta of 1.44, meaning that its share price is 44% more volatile than the S&P 500. Comparatively, Lixte Biotechnology has a beta of -0.11, meaning that its share price is 111% less volatile than the S&P 500. Does the media refer more to CARM or LIXT? In the previous week, Carisma Therapeutics had 6 more articles in the media than Lixte Biotechnology. MarketBeat recorded 6 mentions for Carisma Therapeutics and 0 mentions for Lixte Biotechnology. Lixte Biotechnology's average media sentiment score of 0.00 beat Carisma Therapeutics' score of -0.10 indicating that Lixte Biotechnology is being referred to more favorably in the news media. Company Overall Sentiment Carisma Therapeutics Neutral Lixte Biotechnology Neutral SummaryCarisma Therapeutics beats Lixte Biotechnology on 13 of the 17 factors compared between the two stocks. Ad Behind the MarketsWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Click to get the name and ticker symbol Get Lixte Biotechnology News Delivered to You Automatically Sign up to receive the latest news and ratings for LIXT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LIXT vs. The Competition Export to ExcelMetricLixte BiotechnologyPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.45M$6.57B$5.14B$9.08BDividend YieldN/A3.00%5.09%4.23%P/E Ratio-1.1410.5989.9717.17Price / SalesN/A196.061,117.23117.03Price / CashN/A57.1643.0437.86Price / Book9.005.094.784.78Net Income-$5.09M$151.83M$120.31M$225.60M7 Day Performance-0.26%-2.13%-1.92%-1.23%1 Month Performance21.47%-4.55%13.64%0.46%1 Year Performance-14.29%8.87%28.32%15.25% Lixte Biotechnology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LIXTLixte BiotechnologyN/A$1.98+3.7%N/A-10.4%$4.45MN/A-1.143Gap UpCARMCarisma Therapeutics3.6722 of 5 stars$0.43+6.3%$4.94+1,048.6%-85.6%$17.96M$20.27M-0.2620High Trading VolumePIRSPieris Pharmaceuticals1.2996 of 5 stars$13.60-15.7%N/A+9.7%$17.95M$42.81M-1.12140Gap DownAPREAprea Therapeutics3.1914 of 5 stars$3.19-0.3%$15.50+385.9%-19.9%$17.34M$580,000.00-1.147Analyst ForecastNews CoverageMEIPMEI Pharma3.9163 of 5 stars$2.60-3.7%$7.00+169.2%-59.3%$17.32M$65.30M-0.39100Analyst ForecastSYBXSynlogicN/A$1.47-2.0%N/A-53.1%$17.20M$3.37M-0.366PRPHProPhase Labs3.1815 of 5 stars$0.70+7.5%$11.00+1,471.7%-86.8%$16.71M$12.75M-0.57130High Trading VolumeCYTHCyclo Therapeutics3.2001 of 5 stars$0.58+0.0%$0.95+63.8%-65.2%$16.69M$870,725.00-0.649News CoverageBLRXBioLineRx2.3143 of 5 stars$0.21-7.5%$9.00+4,224.8%-87.8%$16.64M$21.99M-1.0240Analyst ForecastHigh Trading VolumeATHEAlterity Therapeutics2.5794 of 5 stars$2.26-5.8%$6.00+165.5%-15.4%$16.50MN/A0.0010News CoverageFLGCFlora Growth3.0907 of 5 stars$1.22-6.2%$5.00+309.8%-21.6%$16.31M$64.15M0.00280Positive NewsGap DownHigh Trading Volume Related Companies and Tools Related Companies CARM Alternatives PIRS Alternatives APRE Alternatives MEIP Alternatives SYBX Alternatives PRPH Alternatives CYTH Alternatives BLRX Alternatives ATHE Alternatives FLGC Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:LIXT) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersWhy Buffett, Griffin and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredMUST SEE: The most important video in the world right now?If you have a significant amount of money in the stock market right now — or if you're sitting on the sideline...InvestorPlace | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lixte Biotechnology Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lixte Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free LIXT Stock Alerts